Regulated Induced Proximity Targeting Chimeras (RIPTACs) represent a novel therapeutic modality designed to elicit a "Hold-and-Kill" mechanism by cross-linking a tumor-specific target with an essential effector protein (e.g., BRD4), leading to robust cell death. However, validating novel RIPTAC pairs requires rigorous multi-dimensional evaluation. Here, we present a systematic validation platform for new RIPTAC and TCIP pairs. Our strategy initiates with AI-driven (AIDD) structural predictions of ternary protein-protein interactions. At the protein level, biophysical and biochemical assays, including SPR and HTRF, are deployed to quantify binding kinetics and ternary cooperativity. Moving to the cellular context, we utilize NanoBRET, AlphaLISA, and rigorously controlled inducible expression systems to confirm target-dependent induced proximity in live cells. Functionally, extensive cell panel assays demonstrate a strong correlation between biomarker expression (e.g., ESR1 nTPM) and RIPTAC-mediated cytotoxicity, successfully overcoming resistance mechanisms seen with traditional degraders like Fulvestrant. Finally, transcriptomic and biomarker analyses elucidate the distinct mechanism of action, highlighting severe transcriptional stress and unique cell death pathways. Furthermore, we demonstrate the platform's versatility by expanding to novel targets, including p53-Y220C complexes. This integrated workflow streamlines the discovery, optimization, and mechanistic validation of next-generation induced-proximity therapeutics.
Antibody-drug conjugates (ADCs) are key targeted therapies, yet drug resistance remains a major clinical challenge. To address this, we established a panel of 30 well-characterized ADC-resistant cell lines, validated via resistance profiling, RNA-seq, and WES analysis. This platform enables high-throughput screening of novel payloads and combinations to overcome resistance.
Degrader-antibody conjugates (DACs) represent a promising modality for cancer therapy, integrating a tumor-targeting antibody, a protein degrader payload, and a chemical linker into a single molecule. This design combines antibody-mediated tumor specificity with the degrader's ability to eliminate disease-associated proteins. To accelerate DAC development, ICE Bioscience has established a comprehensive evaluation platform enabling end-to-end characterization and assessment of DACs, from in vitro profiling to in vivo pharmacology.
Signal Transducer and Activator of Transcription 6 (STAT6) is a pivotal transcription factor activated downstream of the interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling pathways. It governs the expression of key genes involved in type 2 immune responses, including Th2 cell differentiation, IgE class switching, and M2 macrophage polarization. Dysregulated STAT6 activity has been implicated in a range of diseases, from asthma and atopic dermatitis to fibrosis and immune-evasive tumors.
With the clinical advancement of STAT6-targeting drugs like Kymera’s KT-621 and Recludix’s REX-8756, the demand for precise STAT6 binding profiling is rising—supporting target validation, mechanism studies, and therapeutic development.
Address: Bldg 16, Yd 18, Kechuang 13th St, Etown, Tongzhou Dist, Beijing, 100176, China
Email: marketing@ice-biosci.com
Tel：+86-10-67809840
